Several research and development teams around the world are working towards COVID-19 vaccines. As vaccines are expected to be developed and produced, preparedness and planning for mass vaccination and immunization will become an important aspect of the pandemic management. Mass vaccination has been used by public health agencies in the past and is being proposed as a viable option for COVID-19 immunization. To be able to rapidly and safely immunize a large number of people against SARS-CoV-2, different mass vaccination options are available. Drive-through facilities have been successfully used in the past for immunization against other diseases and for testing during COVID-19. In this paper we introduce a drive-through vaccination simulation tool that can be used to enhance the planning, design, operation, and feasibility and effectiveness assessment of such facilities. The simulation tool is a hybrid model that integrates discrete event and agent-based modeling techniques. The simulation outputs visually and numerically show the average processing and waiting times and the number of cars and people that can be served (throughput values) under different numbers of staff, service lanes, screening, registration, immunization, and recovery times.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7711491 | PMC |
| http://dx.doi.org/10.3390/healthcare8040469 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Understanding and overcoming geographical barriers for scaling up dog vaccinations against rabies.
Sci Rep
December 2024
Department of Mathematics, Manchester University, Manchester, UK.
Rabies causes 59,000 human deaths annually in over 150 countries. Mass dog vaccination (MDV) is key to controlling dog rabies, requiring 70% coverage in the susceptible dog population to eliminate rabies deaths. MDV campaigns must achieve geographical homogeneity of coverage.
View Article and Find Full Text PDFLaboratory safety and immunogenicity evaluation of live attenuated avian infectious bronchitis GI-23 virus vaccine.
Vaccine
December 2024
Poultry Diseases Department, Faculty of Veterinary Medicine, Beni-Suef University, Beni-Suef 62511, Egypt.
Avian infectious bronchitis virus (IBV) is responsible for a highly contagious disease that poses a significant threat to the poultry industry due to its high rates of evolution. The occurrence of vaccination failure can frequently be attributed to the emergence of novel strains that exhibit antigenic divergence from conventional vaccine strains. This study aims to evaluate the safety and efficacy of the Eg/1212B-based live attenuated virus vaccine indicated for immunization of chickens against nephropathogenic GI-23 variant strains reported globally.
View Article and Find Full Text PDFManure odor profiling for flock-level monitoring on commercial layer pullet farms: Vaccination events as a model stressor.
Poult Sci
December 2024
Adaptation Physiology Group, Wageningen University & Research, P.O. Box 338, 6700 AH Wageningen, The Netherlands.
Continuous, non-invasive, and objective methods to detect flock-level responses to stressors, including intestinal health deviations, are currently lacking in poultry. This proof of principle study investigated the potential of manure odor profiling in monitoring stress responses in Lohmann Brown Classic, Lohmann LSL Classic and Lohmann LSL Lite layer pullets. Stressors were represented by a Salmonella vaccination given to the pullets at wk 3 of age (Dataset 1 and Dataset 2) and wk 16 of age (Dataset 4) and a viral/bacterial vaccine cocktail given at wk 12 of age (Dataset 3).
View Article and Find Full Text PDFTargeted and untargeted cross-sectional study for sex-specific identification of plasma biomarkers of COVID-19 severity.
Anal Bioanal Chem
December 2024
Departamento de Análisis Instrumental, Facultad de Farmacia, Universidad de Concepción, Concepción, Chile.
Coronavirus disease 2019 is a highly contagious respiratory illness caused by the coronavirus SARS-CoV-2. Symptoms can range from mild to severe and typically appear 2-14 days after virus exposure. While vaccination has significantly reduced the incidence of severe complications, strategies for the identification of new biomarkers to assess disease severity remains a critical area of research.
View Article and Find Full Text PDFWe describe an outbreak of invasive meningococcal disease (IMD) caused by Neisseria meningitidis serogroup C in Fiji. We created surveillance case definitions and collected data by using standard investigation forms. Bacterial identification, antimicrobial susceptibility testing, and PCR were performed in Fiji.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!